AstraZeneca Says Tagrisso (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial - AZN News | Rallies
AstraZeneca Says Tagrisso (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial A AZN • 2026-09-14 ADAURA phase III trial results
Tagrisso (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in the Adaura phase III trial.
AstraZeneca reports the longest survival data in a global phase III trial for early-stage EGFR-mutated lung cancer.
Tagrisso reduces risk of death by 47% in stages II-IIIA at eight years.
Tagrisso reduces risk of death by 48% in stages IB-IIIA at eight years.
74% of Tagrisso-treated patients were alive at eight years in stages II-IIIA.
79% of Tagrisso-treated patients were alive at eight years in stages IB-IIIA.
Adaura final safety data show Tagrisso profile consistent with no new safety concerns.
XLE
•
2026-09-13
AZN•
